TY - JOUR
T1 - Heparin-induced thrombocytopaenia complicating cardiogenic shock requiring durable mechanical circulatory support
T2 - a case report
AU - Cangialosi, Peter
AU - Dembitzer, Francine
AU - Anyanwu, Anelechi C.
AU - Parikh, Aditya
N1 - Publisher Copyright:
© 2023 The Author(s). Published by Oxford University Press on behalf of the European Society of Cardiology.
PY - 2023/10/1
Y1 - 2023/10/1
N2 - Background: Heparin-induced thrombocytopaenia (HIT) is an immune-mediated reaction to heparin therapy that may lead to life-threatening thrombotic events. This disorder complicates intraoperative heparin use during left ventricular assist device (LVAD) implantation. Case summary: A 52-year-old man presented in acute decompensated heart failure. His admission laboratory studies were consistent with cardiogenic shock with a lactate of 6.1 mmol/L (ref range 0.50-1.99 mmol/L). Echocardiogram and CT scan demonstrated severe biventricular dysfunction and a left ventricular ejection fraction of 10%, as well as left upper lobe segmental pulmonary embolism. He was started on inotropes, diuretics, and a heparin infusion. Following heparin initiation, his platelets had decreased by 63% to a nadir of 39 000/μL (ref range 150 000-450 000/μL) and testing confirmed a diagnosis of HIT. His shock state worsened to INTERMACS 1 necessitating escalation of mechanical support. In preparation for HeartMate 3 LVAD implantation, he received 3 cycles of plasmapheresis with one session of IVIG perioperatively, resulting in a 60% reduction in the titre of heparin-dependent platelet antibodies. He underwent successful LVAD implantation including usage of intraoperative heparin, and was discharged home on post-operative Day 17, where he has remained stable on LVAD support. Discussion: Limited data exist on the perioperative management of patients with HIT undergoing LVAD implantation. Heparin is preferred to other antithrombin agents during surgery due to the availability of an immediate reversal agent. Plasmapheresis with IVIG is a potential management option to decrease heparin-dependent platelet antibodies in patients with HIT to allow for successful LVAD implantation.
AB - Background: Heparin-induced thrombocytopaenia (HIT) is an immune-mediated reaction to heparin therapy that may lead to life-threatening thrombotic events. This disorder complicates intraoperative heparin use during left ventricular assist device (LVAD) implantation. Case summary: A 52-year-old man presented in acute decompensated heart failure. His admission laboratory studies were consistent with cardiogenic shock with a lactate of 6.1 mmol/L (ref range 0.50-1.99 mmol/L). Echocardiogram and CT scan demonstrated severe biventricular dysfunction and a left ventricular ejection fraction of 10%, as well as left upper lobe segmental pulmonary embolism. He was started on inotropes, diuretics, and a heparin infusion. Following heparin initiation, his platelets had decreased by 63% to a nadir of 39 000/μL (ref range 150 000-450 000/μL) and testing confirmed a diagnosis of HIT. His shock state worsened to INTERMACS 1 necessitating escalation of mechanical support. In preparation for HeartMate 3 LVAD implantation, he received 3 cycles of plasmapheresis with one session of IVIG perioperatively, resulting in a 60% reduction in the titre of heparin-dependent platelet antibodies. He underwent successful LVAD implantation including usage of intraoperative heparin, and was discharged home on post-operative Day 17, where he has remained stable on LVAD support. Discussion: Limited data exist on the perioperative management of patients with HIT undergoing LVAD implantation. Heparin is preferred to other antithrombin agents during surgery due to the availability of an immediate reversal agent. Plasmapheresis with IVIG is a potential management option to decrease heparin-dependent platelet antibodies in patients with HIT to allow for successful LVAD implantation.
KW - Cardiogenic shock
KW - Case report
KW - Heparin-induced thrombocytopaenia
KW - IVIG
KW - Mechanical circulatory support
KW - Plasmapheresis
KW - Therapeutic plasma exchange
UR - https://www.scopus.com/pages/publications/85177075977
U2 - 10.1093/ehjcr/ytad496
DO - 10.1093/ehjcr/ytad496
M3 - Article
AN - SCOPUS:85177075977
SN - 2514-2119
VL - 7
JO - European Heart Journal - Case Reports
JF - European Heart Journal - Case Reports
IS - 10
M1 - ytad496
ER -